About imiglucerase i u equivalency
Recombinant enzyme replacement therapy
Used for
- Long-term treatment of type 1 Gaucher disease
- Treatment of some non-neurological symptoms in type 3 Gaucher disease
Usual adult dose
Usually 2.5 units/kg intravenously three times weekly, or 15 units/kg every two weeks; dose is individualized.
Usual dose in children
Usually 2.5 units/kg intravenously three times weekly, or 15 units/kg every two weeks; specialist-individualized.
Common side effects
- Infusion reactions, including fever, chills, flushing, or headache
- Nausea, vomiting, or abdominal pain
- Dizziness or fatigue
- Allergic reactions, rarely severe
Important warnings
- Infusion-related allergic reactions can occur, including anaphylaxis.
- Antibodies may develop and increase the risk of allergic reactions.
- Use under supervision by clinicians experienced in Gaucher disease.
- Not effective for neurological symptoms of type 2 or type 3 Gaucher disease.
Pregnancy
Use when needed to treat Gaucher disease; untreated disease can pose risks during pregnancy.
Breastfeeding
Information is limited; use requires consideration of treatment benefits and potential risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.